Market Research Logo

Global Parkinson's Disease (PD) Drugs Market 2017-2021

About Parkinson's Disease (PD) Drugs

Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by damage to the dopaminergic neurons located in various parts of the brain, including the substantia nigra. This lowers the concentration of dopamine in the striatum by 80%. This decrease in dopamine levels leads to symptoms associated with PD such as tremors, bradykinesia, and muscular rigidity. It is usually diagnosed after the age of 50 years; however, cases of earlier incidence have also been reported.

Technavio’s analysts forecast the global parkinson's disease (PD) drugs market to grow at a CAGR of 3.81% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global parkinson's disease (PD) drugs market for 2017-2021. To calculate the market size, the report considers sales/revenues and market share of the PD drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Parkinson's Disease (PD) Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Boehringer Ingelheim
  • GlaxoSmithKline
  • Novartis
  • Teva Pharmaceutical Industries
Other prominent vendors
  • AbbVie
  • Abital Pharma
  • Addex Therapeutics
  • Biogen
  • Eisai
  • Eli Lilly
  • F. Hoffmann-La Roche
  • H. Lundbeck
  • Impax Laboratories
  • Kyowa Hakko Kirin
  • Otsuka Pharmaceutical
  • Pfizer
  • Prana Biotechnology
  • Reviva Pharmaceuticals
  • SK Biopharmaceuticals
  • Takeda Pharmaceutical
  • UCB
Market driver
  • Rise in geriatric population
  • For a full, detailed list, view our report
Market challenge
  • Entry of generics
  • For a full, detailed list, view our report
Market trend
  • Emergence of biomarkers
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?


Press Release

Technavio Announces the Publication of its Research Report – Global Parkinson's Disease (PD) Drugs Market 2017-2021

Technavio recognizes the following companies as the key players in the global parkinson's disease (PD) drugs market: Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Teva Pharmaceutical Industries.

Other Prominent Vendors in the market are: AbbVie, Abital Pharma, Addex Therapeutics, Biogen, Eisai, Eli Lilly, F. Hoffmann-La Roche, H. Lundbeck, Impax Laboratories, Kyowa Hakko Kirin, Otsuka Pharmaceutical, Pfizer, Prana Biotechnology, Reviva Pharmaceuticals, SK Biopharmaceuticals, Takeda Pharmaceutical, and UCB.

Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is emergence of biomarkers. The global PD drugs market is primarily dominated by dopamine agonist, MAO inhibitors, AChE inhibitors, glutamate inhibitors, and others. Use of these drugs for the treatment of different types of neurodegenerative disorders such as Lewy bodies dementia, movement disorder, and PD indicates that these disorders have common pathological conditions.”

According to the report, one driver in the market is rise in geriatric population. PD is a neurological disorder, often characterized by a decline in motor functions, cognitive, and memory impairments. The cognitive impairment associated with PD may include symptoms such as memory loss, difficulty in understanding words, inability to carry out voluntary activities, failure to identify objects, and others. The risk of developing PD increases with age and is more common among older people. As per the CDC, the projected demographic changes in the US and increasing geriatric population demand better understanding of the pathogenesis of various neurological diseases, including dementia, among older population and is a growing public health concern.

Further, the report states that one challenge in the market is entry of generics. Generic drugs are often introduced once the patent on the branded drugs expires. Patent expiries led to the introduction of less expensive generic drugs in the market. The global PD drugs market has also witnessed the loss of patent exclusivity period of various blockbuster drugs, which has led to the entry of generics during the forecast period. Many generic products currently serve the market. For instance, the patent expiry of top-selling drugs such as Aricept from Eisai has led to decrease in the revenue potential of the market in the recent years, and entry of generic donepezil are hampering the market growth.

Companies Mentioned

Boehringer Ingelheim, GlaxoSmithKline, Novartis, Teva Pharmaceutical Industries, AbbVie, Abital Pharma, Addex Therapeutics, Biogen, Eisai, Eli Lilly, F. Hoffmann-La Roche, H. Lundbeck, Impax Laboratories, Kyowa Hakko Kirin, Otsuka Pharmaceutical, Pfizer, Prana Biotechnology, Reviva Pharmaceuticals, SK Biopharmaceuticals, Takeda Pharmaceutical, and UCB.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
  • Market landscape
    • Market overview
      • Table Global PD drugs market: A snapshot
    • Market size and forecast
      • Table Global PD drugs market 2016-2021 ($ millions)
      • Table Opportunity analysis of global PD drugs market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline landscape
    • Table Pipeline landscape based on number of molecules, 2016
    • Table Key clinical trials
  • Market segmentation by drug class
    • Table Segmentation of global PD drugs market by drug class 2016
    • Table Global PD drugs market share by drug class 2016
    • Dopamine agonist
      • Table Global PD dopamine agonist drugs market 2016-2021 ($ millions)
    • MAO inhibitors
      • Table Global PD MAO inhibitors drugs market 2016-2021 ($ millions)
    • AChE inhibitors
      • Table Global PD AchE inhibitors drugs market 2016-2021 ($ millions)
    • Glutamate inhibitors
      • Table Global PD glutamate inhibitors drugs market 2016-2021 ($ millions)
    • Others
  • Market segmentation based on geography
    • Table Segmentation of global PD drugs market share by geography 2016 and 2021 (%)
    • Table Global PD drugs market revenue by geography 2016-2021 ($ millions)
    • Table Global PD drugs market share by geography 2016-2021 (%)
    • Table PD drugs market scenario in different regions
    • PD drugs market in Americas
      • Table Market scenario in Americas
      • Table PD drugs market in Americas 2016-2021 ($ millions)
    • PD drugs market in EMEA
      • Table Market scenario in EMEA
      • Table PD drugs market in EMEA 2016-2021 ($ millions)
    • PD drugs market in APAC
      • Table Market scenario in APAC
      • Table PD drugs market in APAC 2016-2021 ($ millions)
  • Decisio n framework
  • Drivers and challenges
    • Market drivers
      • Table Geriatric population analysis and estimates in 2000 and 2030 (millions)
    • Market challenges
      • Table Revenue erosion of PD drugs after loss of exclusivity
  • Market trends
    • Emergence of biomarkers
    • Gene therapy to reverse the progression of PD
    • Advancing biomedical science
    • Focus on regenerative therapies for mental disorders
      • Table Planned clinical trials of iPS cell-based therapies
    • High growth potential of mAbs
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global PD drugs market 2016
    • Key news
  • Key vendor analysis
    • Boehringer Ingelheim
      • Table Boehringer Ingelheim: Key highlights
      • Table Boehringer Ingelheim: Strength assessment
      • Table Boehringer Ingelheim: Strategy assessment
      • Table Boehringer Ingelheim: Opportunity assessment
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Key highlights
      • Table GlaxoSmithKline: Strength assessment
      • Table GlaxoSmithKline: Strategy assessment
      • Table GlaxoSmithKline: Opportunity assessment
    • Novartis
      • Table Novartis: Key highlights
      • Table Novartis: Strength assessment
      • Table Novartis: Strategy assessment
      • Table Novartis: Opportunity assessment
    • Teva Pharmaceutical Industries
      • Table Teva Pharmaceutical Industries: Key highlights
      • Table Teva Pharmaceutical Industries: Strength assessment
      • Table Teva Pharmaceutical Industries: Strategy assessment
      • Table Teva Pharmaceutical Industries: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report